百亚股份：Q4外省增长亮眼，品牌全国化成长无虞

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% against the market benchmark within the next six months [19]. Core Insights - The company reported a revenue of 3.25 billion yuan for 2024, representing a year-on-year growth of 51.8%, and a net profit of 285 million yuan, up 19.69% year-on-year. In Q4 alone, revenue reached 930 million yuan, a 39.2% increase year-on-year, while net profit was 47 million yuan, down 16.5% year-on-year [2][4]. Summary by Relevant Sections Revenue and Growth - In 2024, the offline channel generated 1.616 billion yuan in revenue, a 26.8% increase year-on-year, with peripheral provinces showing an impressive growth of 82.1%. E-commerce revenue surged to 1.525 billion yuan, marking a 103.8% increase [4][5]. Product Performance - The company's flagship product line, "Free Point," achieved revenue of 3.037 billion yuan in 2024, reflecting a 60.7% year-on-year growth. The health product series, particularly the probiotic range, experienced even faster growth, with an increasing proportion of mid-to-high-end products contributing to overall revenue [4][5]. Financial Metrics - The gross margin for 2024 was reported at 53.1%, an increase of 2.8 percentage points year-on-year. The gross margin for the "Free Point" sanitary napkin line was 55.7%, up 0.9 percentage points. The net profit margin for 2024 was 8.8%, down 2.4 percentage points, primarily due to an increase in sales expense ratio [5][6]. Profit Forecast - The forecast for net profit from 2024 to 2026 is 290 million yuan, 370 million yuan, and 470 million yuan, respectively, with growth rates of 19.7%, 29.8%, and 27.3% [6]. Valuation - The current stock price corresponds to a 2025 P/E ratio of 27 times. Given the expected growth in 2025 and 2026, the valuation is considered reasonable, with the company's personal care brand expansion showing strong momentum and growth potential exceeding that of comparable companies [6].